PDCD1 and neoplasm: We demonstrated that treatment with CBDCA and anti-PD-1 before surgery increased the ratio of CD103+ DC in total DC in the secondary 4T1 breast tumors by ~1.5-folds (Figures 7B,C, p < 0.01) at Day 35 after the primary tumor implantation.